Increasing Lifestyle Disorders to Push the CRISPR Market to Reach $5872.4 Million by 2028

According to an analysis by Triton Market Research on the global CRISPR market, the industry which generated $850.1 million in 2019, is expected to bloom at a CAGR of 23.95% by 2028.

A study by Triton Market Research with the title ‘Global CRISPR Market,’ covers the Global Analysis and Forecast for 2019-2028 by Application (Genome Editing/Genetic Engineering [Genetically Modified Organisms, Agricultural Biotechnology, Other Genome Editing/Genetic Engineering], CRISPR Plasmid, Human Stem Cells, gRNA Database/Gene Library, Cell Line Engineering), by Product (Vectors, Control Kits, GRNA, Proteins [Cpf1, Cas9, Other Proteins], Plasmids, Design Tools, Library, Other Proteins), by End-user (Agricultural Biotech, Biological Research, Industrial biotech, Therapeutics & Drug Discovery), and by Geographical Region (Asia-Pacific, Latin America, North America, Europe, Middle East and Africa).

CRISPR (Clustered Regularly Interspaced Short Palindrome Repeats) is a powerful and efficient tool used by the researchers for genome editing. With this technology, researchers can permanently modify genes in living cells and may also be used to correct mutations for treating genetic diseases. 

Request Free Sample of the Global CRISPR Market Report @ www.tritonmarketresearch.com/reports/crispr-market#request-free-sample

As per the Triton report, the global CRISPR market is expected to garner $5872.4 million by 2028, and evolve with a CAGR of 23.95% in the forecasted years 2019-2028.

The increasing frequency of cardiovascular diseases across the world, especially in developing countries, is instigating demand for interventional cardiology surgeries and other medical devices, which can be very expensive. The economic growth in these countries has led to the demand for a better healthcare system. This factor is primarily driving the growth of the global CRISPR market.

The rising cases of cancer and other chronic disorders due to the increased environmental factors like stress, smoking, unhealthy eating habits and physical inactivity is pushing the demand for advanced treatments like CRISPR that can cure diseases by eliminating it at the root. However, stringent regulatory guidelines by the government are restraining CRISPR market growth. Various organizations in the world that oppose CRISPR, consider that this technology can lead to disruption and alteration of the genetic blueprints of organisms.

The market for CRISPR is divided into three main segments application, product and end-user. The second main segment, product, divides into vectors, control kits, GRNA, proteins, plasmids, design tools, library and other products. Within the protein segment, the market is divided into Cpf1, Cas9 and other proteins. The first segment, application, is sub-segmented into genome editing/ genetic engineering, CRISPR plasmid, human stem cells, gRNA database/gene library and cell line engineering. While the sub-segment, genome editing/genetic engineering includes genetically modified organisms, agricultural biotechnology and other genome editing/genetic engineering. The third main segment, end-user, is classified into agricultural biotech, biological research, industrial biotech and therapeutics & drug discovery.

As per the geographical outlook, Asia-Pacific is expected to be the fastest-growing region for the CRISPR market in the estimated period. The increasing geriatric population, coupled with the rising prevalence of chronic disorders like cancer and diabetes, are contributing majorly to the growth of the regional CRISPR market. The growing research and development activities in countries like China, is favoring the market growth in Asia-Pacific.

Some of the major corporations involved in the CRISPR market are New England Biolabs, Genedata AG, Integrated DNA Technologies Inc, Origene Technologies Inc, Addgene, Sigma-Aldrich (Merck KGaA), Intellia Therapeutics Inc, Lonza, GeneCopoeia Inc, Transposagen Bio (Hera BioLabs), DiaCarta, Editas Medicine, GenScript, Precision Biosciences, Horizon Discovery Ltd, Thermo Fisher Scientific Inc, Cellectis, Sangamo Therapeutics, Applied StemCell, Caribou Biosciences Inc, and CRISPR Therapeutics.

Purchase this Report @ www.tritonmarketresearch.com/reports/crispr-market#purchase-option


Question & Answer: CRISPR Market

Question 1: Which are the factors majorly driving the growth of the global CRISPR market?

 Answer: The increasing frequency of cardiovascular diseases across the world, especially in developing countries, is instigating demand for interventional cardiology surgeries and other medical devices, which can be very expensive. The economic growth in these countries has led to the demand for a better healthcare system. This factor is majorly driving the growth of the global CRISPR market. The rising cases of cancer and other chronic disorders due to the increased environmental factors like stress, smoking, unhealthy eating habits and physical inactivity is pushing the demand for advanced treatments like CRISPR that can cure diseases by eliminating it at the root.

Question 2: Which factors are restraining the CRISPR market growth?

Answer: Stringent regulatory guidelines by the government are restraining CRISPR market growth. Various organizations in the world that oppose CRISPR, consider that this technology can lead to disruption and alteration of the genetic blueprints of organisms.

Question 3: How is the Asia-Pacific impacting the CRISPR market outlook?

Answer: As per the geographical outlook, Asia-Pacific is expected to be the fastest-growing region for the CRISPR market in the estimated period. The increasing geriatric population, coupled with the rising prevalence of chronic disorders like cancer and diabetes, are contributing majorly to the growth of the regional CRISPR market. The growing research and development activities in countries like China, is favoring the market growth in Asia-Pacific.

Question 4: Which are the major corporations involved in the CRISPR market?

Answer: Some of the major corporations involved in the CRISPR market are New England Biolabs, Genedata AG, Integrated DNA Technologies Inc, Origene Technologies Inc, Addgene, Sigma-Aldrich (Merck KGaA), Intellia Therapeutics Inc, Lonza, GeneCopoeia Inc, Transposagen Bio (Hera BioLabs), DiaCarta, Editas Medicine, GenScript, Precision Biosciences, Horizon Discovery Ltd, Thermo Fisher Scientific Inc, Cellectis, Sangamo Therapeutics, Applied StemCell, Caribou Biosciences Inc, and CRISPR Therapeutics.


Related Report:

Global DNA Vaccines Market

The global DNA vaccines market is set to reach a growth of $37.38 billion by 2027, while progressing at 42.03% of CAGR over the forthcoming period 2019-2027.

Public-Private companies are increasingly making investments towards vaccine development, which can help the DNA vaccines market. The animal healthcare industry is witnessing an upsurge in the expenditure on animal vaccines, including spending on DNA vaccines. The cost-effectiveness and its stability of the DNA vaccines make it favorable in the animal healthcare sector. Recombinant DNA vaccines have been emerging into promising combat against various chronic and infectious diseases. 

Gene therapy is used to replace or correct a particular defective gene in the body. The growing demand for gene-based therapies is paving a way to the DNA vaccine market growth. Clinical trials are increasingly conducted on humans for testing its immunogenicity.

Media Contact
Company Name: Triton Market Research
Contact Person: Matt Dixson
Email: Send Email
Phone: +44 7441 911839
Address:196, wards wharf approach London E16 2EQ
Country: United Kingdom
Website: www.tritonmarketresearch.com/



Source link